{"id":"W2135258573","doi":"10.1016/j.ctrv.2009.12.003","title":"Bevacizumab as a treatment option in advanced renal cell carcinoma: An analysis and interpretation of clinical trial data","year":2010,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Canadian Centre for Applied Research in Cancer Control","keywords":"Medicine; Bevacizumab; Renal cell carcinoma; Oncology; Targeted therapy; Combination therapy; Internal medicine; Kidney cancer; Context (archaeology); Alpha interferon; Cancer; Chemotherapy; Immunology; Interferon","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007261929,0.0007855274,0.004496606,0.001876438,0.0001442755,0.001367399,0.0009428634,0.0006972433,0.001441807],"category_scores_gemma":[0.01479931,0.0003665815,0.003127186,0.002680222,0.0003805141,0.0007571987,0.0003466576,0.0009276475,0.0001681649],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001314251,"about_ca_system_score_gemma":0.002076467,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001282659,"about_ca_topic_score_gemma":0.004801976,"domain_scores_codex":[0.9969073,0.001627403,0.000553379,0.0002476435,0.0006033978,0.00006095133],"domain_scores_gemma":[0.9859688,0.01115939,0.001969292,0.0001737183,0.0006218245,0.0001069193],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.004723623,0.0000937166,0.00233153,0.1916686,0.02524094,0.0001850713,0.0001525699,0.001566626,0.001141624,0.001037488,0.01057208,0.7612861],"study_design_scores_gemma":[0.009543737,0.005364966,0.04079817,0.2308951,0.3091169,0.002871833,0.0004720218,0.003208015,0.002754283,0.004898656,0.3898286,0.0002476924],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00181487,0.9970928,0.000194587,0.0002820453,0.00007150257,0.00006401727,0.0001366418,0.000005533799,0.0003380012],"genre_scores_gemma":[0.02019122,0.9777192,0.0009911654,0.0005354871,0.0001065841,0.00008289489,0.0001777573,0.000008731493,0.0001869953],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007261929,"threshold_uncertainty_score":0.03840524,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2358608435347219,"score_gpt":0.4972069989666378,"score_spread":0.2613461554319159,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}